Asher Bio to Present Preclinical Proof-of-Concept Data for AB248, a Highly Selective CD8-targeted IL-2 Therapy, at SITC 2021

On October 1, 2021 -Asher Biotherapeutics, a biotechnology company developing precisely-targeted immunotherapies for cancer, autoimmune, and infectious diseases, reported that it will present two abstracts at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 36th Annual Meeting (SITC 2021), being held in Washington D.C. and virtually, November 10-14, 2021 (Press release, Asher Biotherapeutics, OCT 1, 2021, View Source [SID1234590661]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Collectively, the presentations demonstrate preclinical proof-of-concept for Asher Bio’s cis-targeting approach and lead program AB248. AB248 is an engineered interleukin-2 (IL-2) immunotherapy, designed specifically to target CD8+ effector T cells. Asher expects to file an investigational new drug application for AB248 in the third quarter of 2022.

Details of the presentations are as follows:

Oral Presentation:
Title: CD8-targeted IL-2 drives potent anti-tumor efficacy and promotes action of tumor specific vaccines
Authors: Hussein Sultan, PhD, Kelly Moynihan, PhD, Yuang Song, Ton Schumacher, PhD, Andy Yeung, PhD, Ivana Djuretic, PhD, and Robert D. Schreiber, PhD
Abstract Number: 578
Session: Cellular Therapies, Saturday 11/13/2021, 3:40 pm – 4:55 pm ET

Poster Presentation:
Title: Selective activation of CD8+ T cells by a CD8-targeted IL-2 results in enhanced anti-tumor efficacy and safety
Authors: Kelly Moynihan, PhD, Danielle Pappas, Terrence Park, Wei Chen PhD, Irene Ni, Paul Bessette PhD, Mike Chin, Ton Schumacher, PhD, Andy Yeung, PhD, and Ivana Djuretic, PhD
Abstract Number: 717
Session: Poster Hall E, Friday 11/12/2021, 7:00 am – 8:30 pm ET

Both abstracts will become available online on the SITC (Free SITC Whitepaper) conference website beginning at 8:00 a.m. ET on Tuesday, November 9, 2021.